Skip to main content
Clinical Trials/JPRN-UMIN000016756
JPRN-UMIN000016756
Completed
未知

Multi-institutional cohort study of evaluating safety and efficacy of surgical treatment for elderly lung cancer - cohort study of surgery for elderly lung cancer

Chest Surgery, St. Marianna University School of Medicine0 sites1,019 target enrollmentMarch 9, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Chest Surgery, St. Marianna University School of Medicine
Enrollment
1019
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 9, 2015
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Chest Surgery, St. Marianna University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Multicenter, retrospective study to assess the safety and efficacy of combination therapy with combination ophthalmic solutions for glaucoma in patients with primary open-angle glaucoma or ocular hypertensioprimary open-angle glaucoma ocular hypertension
JPRN-UMIN000046707Yotsuya Shirato Eye Clinic45
Completed
Not Applicable
Prospective, multicenter study to evaluate the Safety and performance of a syntHetic tissue sealant in reducing fluid lEakage following elective hepatobiLiary anD pancreatic SurgeryFluid leakage following elective hepatobiliary and pancreatic surgery / leakage of bile and pancreatic juices after surgery10019818
NL-OMON55236Polyganics BV, Groningen12
Completed
Not Applicable
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (CLDK378A2120C)non small cell lung cancerlung cancer10029107
NL-OMON44906ovartis3
Active, not recruiting
Phase 1
A study to test the safety and effects of IMG-7289 in patients with myelofibrosis.Patients with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera myelofibrosis (PPV-MF), and post-essential thrombocythaemia myelofibrosis (PET-MF) (collectively referred to as ‘MF’)MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-003811-23-GBImago BioSciences Inc.75
Active, not recruiting
Phase 1
A study to test the safety and effects of IMG-7289 in patients with myelofibrosis
EUCTR2018-003811-23-DEImago BioSciences, Inc.90